|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25.02.26 - 22:15
|
Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
|
|
|
Grew fourth quarter total revenue to $140.6 million, an increase of 19%
Grew fourth quarter testing revenue to $135.8 million, an increase of 21%
Conference call and webcast today at 4:30 p.m. ETSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the fourth quarter and full year ended December 31, 2025.
“We delivered an exceptional finish to 2025, with strong double-digit growth across both Decipher and Afirma and more than 45,000 patients served with our core testing business in the quarter,” said Marc Stapley, Veracyte's chief executive officer. “We are achieving this growth while maintaining best-in-class profitability, with more than $50 million of cash generated from operations in the quarter. Looking ahead, 2026 will be an exciting year as we launch Prosigna as an LDT and TrueMRD, expanding our reach to more patients across the continuum of care while also continuing to invest in clinical evid...
|
|
|
24.02.26 - 23:21
|
CareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial Officer (Business Wire)
|
|
|
Kennedy brings seven years of public company CFO experienceBRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced that Keith Kennedy, the Company's Chief Operating Officer (COO), will also assume the responsibilities of Chief Financial Officer (CFO) and oversee the Company's finance organization effective February 26, 2026.
Kennedy brings to CareDx over 20 years of experience and executive leadership in healthcare including global diagnostics, biopharma services, and contract development and manufacturing organization (CDMO). Kennedy has served as our Chief Operating Officer since September 2024. Prior to joining us, Kennedy served as CFO at PharmaLogic Holdings Corp from April 2022 to September 2024. At Veracyte, Kennedy served in various roles from ...
|
|
|
04.02.26 - 23:18
|
Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 (Business Wire)
|
|
|
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and full-year 2025 after the close of market on Wednesday, February 25, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/motsphxv. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://investor.veracyte.com/events-presentations.
The conference call dial-ins can be accessed by registering via this link.
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower cl...
|
|
|
|
|
|
|
|
|
11.01.26 - 22:33
|
Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Business Wire)
|
|
|
Grew full-year revenue to between $515 million and $517 million, an increase of 16%SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025.
Preliminary Unaudited Financial Results
For the fourth quarter ended December 31, 2025, as compared to the same period of 2024, Veracyte expects to report:
Total revenue of between $138 million and $140 million, an increase of between 16% and 18%
Testing revenue of between $134 million and $136 million, an increase of between 19% and 21%
Testing volume of approximately 45,500, an increase of 16%
For the full year ended December 31, 2025, as compared to the same period of 2024, Veracyte expects to report:
Total revenue of between $515 million and $517 million, an increase of approximately 16%
Testing revenue of between $491 million and $493 million, an increase of approximately 17% to 18%
Testin...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
